002603 Shijiazhuang Yiling Pharmaceutical
- 19.58
- +0.13+0.67%
Shijiazhuang Yiling Pharmaceutical News
Express News | Eling Pharmaceutical: Revenue from cardiovascular products exceeded 4.7 billion yuan, and the research and development of patented traditional Chinese medicine was fruitful
Express News | Eling Pharmaceutical: Independent director Han Zhiguo died due to illness
Express News | Eling Pharmaceutical: Net profit in the first quarter fell 74.73% year on year
Eling Pharmaceutical (002603.SZ): Jinlida granules have not yet conducted clinical studies on “weight loss” indications
Gelonghui, April 10 | Eling Pharmaceutical (002603.SZ) said on an interactive platform that Jinlida granules have not conducted clinical research on “weight loss” indications. In 2015, the “Randomized, double-blind, placebo-controlled, multicenter clinical trial of efficacy and safety of metformin monotherapy patients with type 2 diabetes after administration of Jinrida granules” led by the Chinese Academy of Traditional Chinese Medicine Guanganmen Hospital and the University of Chicago Chinese Medicine Research Office, was published in “Plos One” magazine. The results showed that in diet control, exercise therapy, and dimethylbisubin
Eling Pharmaceutical (002603.SZ): Currently not involved in medical device-related business
Glonghui, December 22|An investor asked Yiling Pharmaceutical (002603.SZ) on the investor interactive platform, “Does your company have any plans to develop in the direction of medical devices?” The company replied that the company is currently not involved in medical device-related business.
Yiling Pharmaceutical Gets Nod for China Clinical Trial of Tracheobronchitis Drug
Shijiazhuang Yiling Pharmaceutical (SHE:002603) obtained approval from China's National Medical Products Administration to conduct clinical trials into Lianhua Qingke granules. The pharmaceutical comp
Beishui bought SMIC and CNOOC for about HK$200 million each, sold Tencent for over HK$400 million; Nanshui sold CMB for over 300 million yuan
Today, South Capital's net purchase of Hong Kong stocks was HK$348 million. SMIC, CNOOC, and Xiaopeng Motor-W received net purchases of HK$216 million, HK$204 million, and HK$95.36 million respectively; Tencent Holdings, China Mobile, and Ideal Auto -W received net sales of HK$405 million, HK$252 million, and HK$222 million respectively.
Changes in A-shares | Influenza Infusion Stock, Yiling Pharmaceutical Co., Ltd. has been rising for 3 days, and the registration application for the new drug “Xinqi Nose Tablets” has been accepted
Gelonghui November 27 | Yiling Pharmaceutical (002603.SZ) has been rising for 3 days, now up 3.54% to 26.89 yuan. The stock price hit a new high in nearly half a year, with a total market value of 44.93 billion yuan. Yiling Pharmaceutical recently announced that Beijing Yiling, a wholly-owned subsidiary of the company, has received a “Notice of Acceptance” issued by the State Drug Administration, and that the registration application for the new drug “Xinqi Tongtong Nose Tablets” submitted by Beijing Yiling has been officially accepted. Xinqi Nose Relief Tablets are a Class 1.1 traditional Chinese medicine innovative drug independently developed by the company. Its functional treatment is: it boosts qi, fixes the meter, and strengthens the spleen. It is used for persistent allergic rhinitis, pulmonary insufficiency, and spleen failure. Symptoms include sneezing, runny nose,
Yiling Pharmaceutical (002603.SZ): New drug registration application for Xinqi Tongnose tablets accepted
Yiling Pharmaceutical (002603.SZ) announced that Beijing Yiling Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company (“Beijing...
Yiling Pharmaceutical's Lianhua Qingke Tablets Gets Nod to Become Over-the-Counter Drug; Shares Up 4%
Shijiazhuang Yiling Pharmaceutical (SHE:002603) received approval from China's National Medical Products Administration to convert Lianhua Qingke tablets into an over-the-counter drug. The traditional
Yiling Pharmaceutical Gets Nod to Trial Huoxia Cold Granules
Shijiazhuang Yiling Pharmaceutical (SHE:002603) will conduct clinical trials into traditional Chinese medicine huoxia cold granules after obtaining the approval of China's National Medical Products Ad
An evidence-based original study on proprietary Chinese medicines appeared in top international medical journals for the first time! Eling Pharmaceutical's Tongxinluo Reduces Risk of Cardiogenic Death by 30%
① The “Study on the Myocardial Protective Effects of China Tongxinluo in the Treatment of Acute Myocardial Infarction (CTS-AMI)” led by Professor Yang Yuejin of Fuwai Hospital of the Chinese Academy of Medical Sciences published original research results in “JAMA”. This is the first time that an evidence-based original study of a proprietary Chinese medicine has appeared in a top international journal. ② Tongxinuo can significantly reduce the risk of 30-day Macces events by about 36% and the risk of cardiogenic death by 30%.
Express News | Yiling Pharmaceutical: The clinical trial application for the traditional Chinese medicine Huaxia cold granule drug was approved, and the results of the Tongxinluo myocardial protection research project for acute myocardial infarction were released
[BT Financial Report Instantaneous Analysis] Yiling Pharmaceutical's 2023 Three-Quarter Report: Steady Growth in Performance, Significant Decline in Net Cash Flow
This financial report was announced on 2023-10-27 18:59:08 Eling Pharmaceutical (stock code: 002603) is a pharmaceutical industry company focusing on the field of traditional Chinese medicine. In recent years, China has vigorously developed the traditional Chinese medicine business and promoted the reform and development of traditional Chinese medicine. Ling Pharmaceutical has responded positively to national policies, is committed to R&D and innovation in traditional Chinese medicine, and promoted the upgrading and development of the traditional Chinese medicine industry. In terms of assets and liabilities, Eling Pharmaceutical's total assets for the third quarter of 2023 were 17.435 billion yuan, up from 16.338 billion yuan at the end of the previous year. Total liabilities were $5.587 billion, slightly higher than
Eling Pharmaceutical (002603) 2023 Third Quarter Report Review: Short-term performance under pressure, R&D has been fruitful
Matters: The company released its 2023 three-quarter report. The company's revenue was 8.575 billion yuan (+7.91%), and net profit was 1,759 billion yuan (+24.35%). In the third quarter alone, the company's revenue was 17.84
Yiling Pharmaceutical (002603): Short-term performance under pressure, R&D pipeline enters the implementation period
Event: The company released its 2023 three-quarter report: 23Q1-3 achieved revenue of 8.575 billion yuan, an increase of 7.91% over the previous year, net profit of 1,759 billion yuan, an increase of 24.35% over the previous year, and deducted non-net profit of 16
Yiling Pharmaceutical (002603): Short-term performance under pressure, patent Chinese medicine research and development continues to advance
Event Overview In 23Q1-Q3, the company achieved revenue of 8.575 billion yuan, yoy +7.9%; net profit of 1,759 billion yuan, yoy +24.3%; net profit after deduction of 1,640 billion yuan, y
Yiling Pharmaceutical (002603): Short-term R&D work in the respiratory sector continues to advance under pressure
Matters: The company released its three-quarter report for 2023: In the first three quarters of 2023, the company achieved operating income of 8.575 billion yuan (+7.91%), net profit of 1,759 billion yuan (+24.35%), net profit of 1,759 billion yuan (+24.35%), deducting non-net profit 16
Eling Pharmaceutical (002603): Short-term performance under pressure, insisting on innovative drug research and development to tap endogenous growth potential
Event: Eling Pharmaceutical announced its report for the third quarter of 2023. The company's revenue for the first three quarters of 2023 was 8.575 billion yuan (YOY +7.91%), and net profit was 1,759 billion yuan (YOY+24.3 billion)
Eling Pharmaceutical (002603): COVID-19 performance continues to be digested, and innovative products are expected to continue to grow
Event: The company released its 2023 three-quarter report. In the first three quarters of 2023, the company achieved revenue of 8.575 billion yuan (yoy +7.91%) and net profit of 1,759 billion yuan (yoy +24.35%), deducted
Analysis
Price Target
No Data
